Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.01, up 3.41% on the session, giving a market capitalisation of $1.1M. On trailing twelve-month figures it carries a trailing P/E of -0.17, a net margin of -29.9%. Its beta of -1.34 implies it has historically moved less than the broad market.
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Evofem Biosciences, Inc. is most often compared with the following Healthcare names: